TY - JOUR T1 - Integrated Analyses of Growth Differentiation Factor-15 Concentration and Cardiometabolic Diseases in Humans JF - medRxiv DO - 10.1101/2021.12.15.21267719 SP - 2021.12.15.21267719 AU - Susanna Lemmelä AU - Eleanor M. Wigmore AU - Christian Benner AU - Aki Havulinna AU - Rachel M. Y. Ong AU - Tibor Kempf AU - Kai C. Wollert AU - Stefan Blankenberg AU - Tanja Zeller AU - James E. Peters AU - Veikko Salomaa AU - Maria Fritsch AU - Ruth March AU - Aarno Palotie AU - Mark Daly AU - Adam S. Butterworth AU - Mervi Kinnunen AU - Dirk S. Paul AU - Athena Matakidou Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/16/2021.12.15.21267719.abstract N2 - Growth differentiation factor 15 (GDF15) is a stress response cytokine that is elevated in several cardiometabolic diseases and has attracted interest as a potential therapeutic target. To further explore the association of GDF15 with human disease, we conducted a broad study into the phenotypic and genetic correlates of GDF15 concentration in up to 14,099 individuals. Assessment of 772 traits across 6,610 participants in FINRISK identified associations of GDF15 concentration with a range of phenotypes including all-cause mortality, cardiometabolic disease, respiratory diseases and psychiatric disorders as well as inflammatory markers. A meta-analysis of genome-wide association studies (GWAS) of GDF15 concentration across 3 different assay platforms (n=14,099) confirmed significant heterogeneity due to a common missense variant rs1058587 in GDF15, potentially due to epitope-binding artefacts. After conditioning on rs1058587, statistical fine-mapping identified 4 independent putative causal signals at the locus. Mendelian randomisation (MR) analysis did not find evidence of a causal relationship between GDF15 concentration and cardiometabolic traits. Using reverse MR, we identified a potential causal association of body mass index on GDF15 (IVW pFDR=0.0072). Taken together, our data do not support a role for elevated GDF15 concentrations as a causal factor in human cardiometabolic disease but support its role as a biomarker of metabolic stress.Competing Interest StatementEMW, RM, DSP and AM are employees of AstraZeneca. RMYO is currently an employee of GlaxoSmithKline (although was not when this work was carried out). AB reports grants outside of this work from Biogen, BioMarin, Bioverativ, Merck, Novartis, Pfizer and Sanofi and personal fees from Novartis. VS has received honoraria from Novo Nordisk and Sanofi for consulting. He also has ongoing research collaboration with Bayer Ltd (All outside this work).Funding StatementRachel Ong is co-funded by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [*]. VS has been supported by the Finnish Foundation for Cardiovascular Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:FINRISK study was approved by the Ethics Committee of Helsinki and Uusimaa Hospital District. Informed consent was obtained from all participants and the INTERVAL study was approved by the National Research Ethics Service (11/EE/0538). All study participants provided informed consent and the UK Biobank has approval from the North-West Multi-centre Research Ethics Committee (MREC; 11/NW/0382).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary data produced in the present study are available upon reasonable request to the authors ER -